Data Sheet ABILIFYTM - Medsafe
NZ_DS_Abilify_V2.1_ August2016 - 2 - PHARMACOLOGY Pharmacodynamics The mechanism of action of ABILIFYTM, as well as other drugs having efficacy in schizophrenia and bipolar disorder, is unknown. However, it has been proposed that the efficacy of ABILIFYTM is mediated through a combination of partial agonist activity at dopamine D
Download Data Sheet ABILIFYTM - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Pharmacology Self-Study Manual for Nurses
dbhdduniversity.comPharmacology Self-Study Manual for Nurses 2012 Prepared by: Jerry Harris, MSN, RN, CNS Approved by: Statewide Nursing Leadership Committee & Division Medical Executive Committee
Medication Alternatives for the Elderly
healthinsight.orgMedication Alternatives for the Elderly Updated 8/8/07 The following table details the drugs to avoid and the recommended agents to be considered as alternatives.
Sign-up Form for the Bristol-Myers Squibb Patient ...
spokaneresourcegroup.comNOU S13UB00168-01 02/13 NOUS13UB00168-01 02/13 NOUS13UB00168-01 02/13 Sign-up Form for the Bristol-Myers Squibb Patient Assistance Foundation
Patient Education ARIPIPRAZOLE - ORAL - doctorsuh.com
www.doctorsuh.comPatient Education ARIPIPRAZOLE - ORAL IMPORTANT NOTE: The following information is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional.
ANTIPSYCHOTIC MEDICATIONS (Atypicals Page 1) Used for ...
www.leeheymd.comANTIPSYCHOTIC MEDICATIONS ("Atypicals" Page 2) Used for Psychosis, Schizophrenia, Bipolar Disorder, Severe Impulsive Aggression, Tourette's, Paranoia, Depression, Anxiety, Autism
![ders3.ppt [Uyumluluk Modu] - ogelk.net](/cache/preview/2/d/8/f/8/5/6/4/thumb-2d8f8564415028747f3771ca166fbffe.jpg)
ders3.ppt [Uyumluluk Modu] - ogelk.net
www.ogelk.netEtki mekanizmaları • Dopamin blokajı yaparlar – Mezolimbik yolda blokaj > pozitif belirtiler – Mezokortikal yol > negatif belirtiler • DiDopamin ve serotitonin bl k jblokajı yaparlar